Review article: Prevention of inflammatory bowel disease—The path forward

Sérgio Bronze,Manasi Agrawal,Jean‐Frédéric Colombel,Joana Torres,Ryan C. Ungaro

DOI: https://doi.org/10.1111/apt.18263

IF: 9.524

2024-10-16

Alimentary Pharmacology & Therapeutics

Abstract:Alimentary Pharmacology &Therapeutics, Volume 60, Issue 9, Page 1166-1175, November 2024.

pharmacology & pharmacy,gastroenterology & hepatology

What problem does this paper attempt to address?

Anti-cytokine Therapy and Small Molecule Agents for the Treatment of Inflammatory Bowel Disease

Yuancong Jiang,Dan Kong,Xudong Miao,Xinmiao Yu,Zelai Wu,Han Liu,Weihua Gong

DOI: https://doi.org/10.1684/ecn.2021.0472

2021-01-01

European Cytokine Network

Abstract:Inflammatory bowel disease (IBD), including Crohn disease and ulcerative colitis, with multifactorial etiologies has led to a global health-associated burden in many countries. Substantial efforts are devoted to understand the pathogenesis, behavioral and environmental triggers, which may be specifically valuable for the treatment of IBD. The specific pathogenesis underlying IBD is as yet incompletely understood. The use of anti-cytokine therapy and small molecule agents targeting the immune system is thought to restore the body's intestinal barrier function and relieve inflammation with manageable adverse effects. In this review, we report recent advances in anti-cytokine therapy and treatment with small molecule agents for the management of IBD.
Review article: Novel therapies in inflammatory bowel disease – An update for clinicians

Nurulamin M. Noor,Aoibh Bourke,Sreedhar Subramanian

DOI: https://doi.org/10.1111/apt.18294

IF: 9.524

2024-10-16

Alimentary Pharmacology & Therapeutics

Abstract:Alimentary Pharmacology &Therapeutics, Volume 60, Issue 9, Page 1244-1260, November 2024.

pharmacology & pharmacy,gastroenterology & hepatology
Inflammatory bowel disease in 2024 and beyond

Richard B. Gearry,Cynthia H. Seow,Sreedhar Subramanian

DOI: https://doi.org/10.1111/apt.18295

IF: 9.524

2024-10-16

Alimentary Pharmacology & Therapeutics

Abstract:Alimentary Pharmacology &Therapeutics, Volume 60, Issue 9, Page 1164-1165, November 2024.

pharmacology & pharmacy,gastroenterology & hepatology
A Review of Compounds for Prevention of Colorectal Cancer

Akhileshwar Namani,Jing Li,Xiu Jun Wang,Xiuwen Tang

DOI: https://doi.org/10.1007/s40495-017-0101-6

2017-01-01

Current Pharmacology Reports

Abstract:Purpose of Review Colorectal cancer (CRC) is the second most commonly diagnosed and one of the leading causes of mortality in cancer patients. CRC occurs due to the complications of chronic inflammatory disorders of the colon. Although the clinical features and molecular mechanisms associated with the CRC is not clear, but discovery of early diagnostic markers and the emergence of safe and effective chemopreventive agents plays a key role in preventing CRC. The purpose of this review is to elucidate and emphasize the different pathways associated with CRC and summarizes the compounds targeting the prevention of CRC. Recent Findings Researchers around the world have identified many potential phytochemical and synthetic compounds for the prevention and treatment of CRC. Based on previous and recent findings, we have reported series of natural and synthetic chemopreventive compounds which affects the specific pathways in CRC. These active chemicals can block CRC-associated signaling pathways, thereby reducing the risk of CRC. Summary This review summarized the CRC pathogenesis, risk factors, difference between sporadic colorectal cancer (SCC) and colitis-associated colorectal cancer (CAC), CRC-related signaling pathways, and chemopreventive compounds against CRC in vitro and in vivo studies. Understanding the mechanistic effects of these compounds is critical for the prevention and therapeutic usage in patients with a high risk of CRC.
Review article: Measuring disease severity in inflammatory bowel disease – Beyond treat to target

Akhilesh Swaminathan,Andrew S. Day,Miles P. Sparrow,Laurent Peyrin‐Biroulet,Corey A. Siegel,Richard B. Gearry

DOI: https://doi.org/10.1111/apt.18231

IF: 9.524

2024-10-16

Alimentary Pharmacology & Therapeutics

Abstract:Alimentary Pharmacology &Therapeutics, Volume 60, Issue 9, Page 1176-1199, November 2024.

pharmacology & pharmacy,gastroenterology & hepatology
Review article: Optimisation of biologic (monoclonal antibody) therapeutic response in inflammatory bowel disease

Thanaboon Chaemsupaphan,Rupert W. Leong,Niels Vande Casteele,Cynthia H. Seow

DOI: https://doi.org/10.1111/apt.18228

IF: 9.524

2024-10-16

Alimentary Pharmacology & Therapeutics

Abstract:Alimentary Pharmacology &Therapeutics, Volume 60, Issue 9, Page 1234-1243, November 2024.

pharmacology & pharmacy,gastroenterology & hepatology
Research advancements and perspectives of inflammatory bowel disease: A comprehensive review

Junyi Bai,Ying Wang,Fuhao Li,Yueyao Wu,Jun Chen,Meng Li,Xi Wang,Bin Lv

DOI: https://doi.org/10.1177/00368504241253709

IF: 1.512

2024-05-25

Science Progress

Abstract:Science Progress, Volume 107, Issue 2, April-June 2024. Inflammatory bowel disease (IBD) is a chronic inflammatory disease with increasing incidence, such as Crohn's disease and ulcerative colitis. The accurate etiology and pathogenesis of IBD remain unclear, and it is generally believed that it is related to genetic susceptibility, gut microbiota, environmental factors, immunological abnormalities, and potentially other factors. Currently, the mainstream therapeutic drugs are amino salicylic acid agents, corticosteroids, immunomodulators, and biological agents, but the remission rates do not surpass 30–60% of patients in a real-life setting. As a consequence, there are many studies focusing on emerging drugs and bioactive ingredients that have higher efficacy and long-term safety for achieving complete deep healing. This article begins with a review of the latest, systematic, and credible summaries of the pathogenesis of IBD. In addition, we provide a summary of the current treatments and drugs for IBD. Finally, we focus on the therapeutic effects of emerging drugs such as microRNAs and lncRNAs, nanoparticles-mediated drugs and natural products on IBD and their mechanisms of action.

multidisciplinary sciences
Potential interventions and interactions of bioactive polyphenols and functional polysaccharides to alleviate inflammatory bowel disease - A review

Muhammad Salman Farid,Bakhtawar Shafique,Rui Xu,Łukasz Łopusiewicz,Changhui Zhao

DOI: https://doi.org/10.1016/j.foodchem.2024.140951

2024-08-22

Abstract:Inflammatory bowel disease is a multifaceted condition that is influenced by nutritional, microbial, environmental, genetic, psychological, and immunological factors. Polyphenols and polysaccharides have gained recognition for their therapeutic potential. This review emphasizes the biological effects of polyphenols and polysaccharides, and explores their antioxidant, anti-inflammatory, and microbiome-modulating properties in the management of inflammatory bowel disease (IBD). However, polyphenols encounter challenges, such as low stability and low bioavailability in the colon during IBD treatment. Hence, polysaccharide-based encapsulation is a promising solution to achieve targeted delivery, improved bioavailability, reduced toxicity, and enhanced stability. This review also discusses the significance of covalent and non-covalent interactions, and simple and complex encapsulation between polyphenols and polysaccharides. The administration of these compounds in appropriate quantities has proven beneficial in preventing the development of Crohn's disease and ulcerative colitis, ultimately leading to the management of IBD. The use of polyphenols and polysaccharides has been found to reduce histological scores and colon injury associated with IBD, increase the abundance of beneficial microbes, inhibit the development of colitis-associated cancer, promote the production of microbial end-products, such as short-chain fatty acids (SCFAs), and improve anti-inflammatory properties. Despite the combined effects of polyphenols and polysaccharides observed in both in vitro and in vivo studies, further human clinical trials are needed to comprehend their effectiveness on inflammatory bowel disease.
Disease prevention trials in IBD: feasibility to future outlook

Sailish Honap,Nelly Agrinier,Silvio Danese,Laurent Peyrin-Biroulet

DOI: https://doi.org/10.1038/s41575-024-00984-3

2024-09-22

Nature Reviews Gastroenterology & Hepatology

Abstract:Therapeutic advances in inflammatory bowel disease (IBD) have been universally directed towards patients with established disease to control inflammation, ameliorate symptoms and hinder disease progression, but preventing IBD development or delaying its onset are highly attractive. This Comment discusses the emerging approaches and future promises of interventional disease prevention trials in IBD.

gastroenterology & hepatology
Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives

Supriya Roy,Suneela Dhaneshwar

DOI: https://doi.org/10.3748/wjg.v29.i14.2078

IF: 5.374

2023-04-14

World Journal of Gastroenterology

Abstract:Experimental evidence supports the fact that changes in the bowel microflora due to environmental or dietary factors have been investigated as implicating factors in the etiopathogenesis of inflammatory bowel disease (IBD). The amassing knowledge that the inhabited microbiome regulates the gut physiology and immune functions in IBD, has led researchers to explore the effectiveness of prebiotics, probiotics, and synbiotics in treating IBD. This therapeutic approach focuses on restoring the dynamic balance between the microflora and host defense mechanisms in the intestinal mucosa to prevent the onset and persistence of intestinal inflammation. Numerous microbial strains and carbohydrate blends, along with their combinations have been examined in experimental colitis models and clinical trials, and the results indicated that it can be an attractive therapeutic strategy for the suppression of inflammation, remission induction, and relapse prevention in IBD with minimal side effects. Several mechanisms of action of probiotics (for <i>e.g., Lactobacillus</i> species, and <i>Bifidobacterium</i> species) have been reported such as suppression of pathogen growth by releasing certain antimicrobial mediators (lactic and hydrogen peroxide, acetic acid, and bacteriocins), immunomodulation and initiation of an immune response, enhancement of barrier activity, and suppression of human T-cell proliferation. Prebiotics such as lactulose, lactosucrose, oligofructose, and inulin have been found to induce the growth of certain types of host microflora, resulting in an enriched enteric function. These non-digestible food dietary components have been reported to exert anti-inflammatory effects by inhibiting the expression of tumor necrosis factor-α-related cytokines while augmenting interleukin-10 levels. Although pro-and prebiotics has established their efficacy in healthy subjects, a better understanding of the luminal ecosystem is required to determine which specific bacterial strain or combination of probiotics and prebiotics would prove to be the ideal treatment for IBD. Clinical trials, however, have given some conflicting results, requiring the necessity to cite the more profound clinical effect of these treatments on IBD remission and prevention. The purpose of this review article is to provide the most comprehensive and updated review on the utility of prebiotics, probiotics, and synbiotics in the management of active Crohn's disease and ulcerative colitis/pouchitis.

gastroenterology & hepatology
Reviewing the potential of probiotics, prebiotics and synbiotics: advancements in treatment of ulcerative colitis

Apurva Jadhav,Suresh Jagtap,Suresh Vyavahare,Archana Sharbidre,Bipinraj Kunchiraman

DOI: https://doi.org/10.3389/fcimb.2023.1268041

IF: 6.073

2023-12-09

Frontiers in Cellular and Infection Microbiology

Abstract:Inflammatory bowel diseases (IBD) like Crohn's and ulcerative colitis (UC) are multifactorial pathologies caused by environmental factors and genetic background. UC is a chronic inflammatory disorder that specifically targets the colon, resulting in inflammation. Various chemical interventions, including aminosalicylates, corticosteroids, immunomodulators, and biological therapies, have been extensively employed for the purpose of managing symptoms associated with UC. Nevertheless, it is important to note that these therapeutic interventions may give rise to undesirable consequences, including, but not limited to, the potential for weight gain, fluid retention, and heightened vulnerability to infections. Emerging therapeutic approaches for UC are costly due to their chronic nature. Alternatives like synbiotic therapy, combining prebiotics and probiotics, have gained attention for mitigating dysbiosis in UC patients. Prebiotics promote beneficial bacteria proliferation, while probiotics establish a balanced gut microbiota and regulate immune system functionality. The utilisation of synbiotics has been shown to improve the inflammatory response and promote the resolution of symptoms in individuals with UC through the stimulation of beneficial bacteria growth and the enhancement of intestinal barrier integrity. Hence, this review article aims to explore the potential benefits and underlying reasons for incorporating alternative approaches in the management of UC with studies performed using prebiotics, probiotics, and synbiotics to treat ulcerative colitis and to highlight safety and considerations in UC and future perspectives. This will facilitate the utilisation of novel treatment strategies for the safer and more efficacious management of patients with UC.

immunology,microbiology
Gastrointestinal microbiota-directed nutritional and therapeutic interventions for inflammatory bowel disease: opportunities and challenges

Devendra Paudel,Divek V T Nair,Grace Joseph,Rita Castro,Amit K Tiwari,Vishal Singh

DOI: https://doi.org/10.1093/gastro/goae033

2024-04-27

Abstract:Evidence-based research has confirmed the role of gastrointestinal microbiota in regulating intestinal inflammation. These data have generated interest in developing microbiota-based therapies for the prevention and management of inflammatory bowel disease (IBD). Despite in-depth understanding of the etiology of IBD, it currently lacks a cure and requires ongoing management. Accumulating data suggest that an aberrant gastrointestinal microbiome, often referred to as dysbiosis, is a significant environmental instigator of IBD. Novel microbiome-targeted interventions including prebiotics, probiotics, fecal microbiota transplant, and small molecule microbiome modulators are being evaluated as therapeutic interventions to attenuate intestinal inflammation by restoring a healthy microbiota composition and function. In this review, the effectiveness and challenges of microbiome-centered interventions that have the potential to alleviate intestinal inflammation and improve clinical outcomes of IBD are explored.
Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease—authors' reply

Abhinav Vasudevan,Danny Con,Daniel R. Langenberg,Daniel R. van Langenberg

DOI: https://doi.org/10.1111/apt.17895

IF: 9.524

2024-02-26

Alimentary Pharmacology & Therapeutics

Abstract:Alimentary Pharmacology &Therapeutics, Volume 59, Issue 6, Page 794-794, March 2024.

pharmacology & pharmacy,gastroenterology & hepatology
Inflammatory Bowel Disease and Risk of Colorectal Cancer: An Overview From Pathophysiology to Pharmacological Prevention

Marianna Lucafò,Debora Curci,Martina Franzin,Giuliana Decorti,Gabriele Stocco

DOI: https://doi.org/10.3389/fphar.2021.772101

IF: 5.6

2021-10-20

Frontiers in Pharmacology

Abstract:Increased risk of colorectal cancer (CRC) in inflammatory bowel disease (IBD) patients has been attributed to long-standing chronic inflammation, with the contribution of genetic alterations and environmental factors such as the microbiota. Moreover, accumulating data indicate that IBD-associated CRC (IBD-CRC) may initiate and develop through a pathway of tumorigenesis distinct from that of sporadic CRC. This mini-review summarizes the current knowledge of IBD-CRC, focusing on the main mechanisms underlying its pathogenesis, and on the important role of immunomodulators and biologics used to treat IBD patients in interfering with the inflammatory process involved in carcinogenesis.

pharmacology & pharmacy
The Role of Diet in Inflammatory Bowel Disease Onset, Disease Management, and Surgical Optimization

Kelly Issokson,Dale Young Lee,Andres J. Yarur,James D. Lewis,David L. Suskind

DOI: https://doi.org/10.14309/ajg.0000000000003085

2024-09-21

The American Journal of Gastroenterology

Abstract:The concept of using diet as therapy in inflammatory bowel disease (IBD) is of interest to clinicians and patients. Once considered to play a minor role, diet is now known to affect not only disease onset but may also serve as a therapeutic tool for inducing and maintaining remission and improving surgical outcomes. Further research is needed to fully elucidate how, when, and in whom diet therapies may be best applied to improve clinical and disease outcomes. The aim of this review is to summarize current research findings and serve as a tool to help facilitate patient-clinician conversations.

gastroenterology & hepatology
Interventional inflammatory bowel disease: current and future practice

Benjamin Clement,Juan Reyes Genere

DOI: https://doi.org/10.1097/mog.0000000000001028

2024-04-16

Current Opinion in Gastroenterology

Abstract:Purpose of review Inflammatory bowel diseases (IBD) are associated with several well described neoplastic and structural complications. Increasing disease prevalence, healthcare barriers, and medication refractory phenotypes contribute to ongoing complications despite significant strides in medical management. Enhancements in endoscopic technology and techniques have allowed a minimally invasive approach for what has historically required surgery. In this article, we review the current and future landscape of endoscopic IBD intervention. Recent findings Endoscopic resection is the first line for managing conventional and complex colitis-associated dysplasia. Evidence supporting endoscopic submucosal dissection is mounting, yet there is a paucity of studies evaluating modified endoscopic mucosal resection techniques or hybrid endoscopic submucosal dissection. We also have more clarity in how best to approach fibrostenotic disease, as we learn how to position endoscopic stricturotomy and stenting, relative to balloon dilation. Finally, applications in managing penetrating and postsurgical complications have been described, but still require further study. Summary While important knowledge gaps still exist, the application of endoscopic therapies in IBD is more refined, especially within the management of colitis-associated dysplasia and strictures. The indications for endoscopy in perianal disease and other penetrating manifestations of Crohn's disease presents exciting opportunities for growth.

gastroenterology & hepatology
Prospective therapeutic targets and recent advancements in the treatment of inflammatory bowel disease

Akshit Sinha,Supriya Roy

DOI: https://doi.org/10.1080/08923973.2024.2381756

Abstract:Objective: Inflammatory Bowel Disease (IBD) poses a persistent challenge in the realm of gastroenterology, necessitating continual exploration of innovative treatment strategies. The limited efficacy and potential side effects associated with existing therapeutic modalities underscore the urgent need for novel approaches in IBD management. This study aims to examine potential therapeutic targets and recent advancements in understanding the disease's intricate pathogenesis, with a spotlight on the gut microbiome, immune dysregulation, and genetic predispositions. Methods: A comprehensive review was conducted to delve into the pressing demand for new avenues in IBD treatment. The study examined potential therapeutic targets such as phosphodiesterase 4 (PDE4) inhibitors, immune system modulators, Tyrosine kinase receptors (TYK), Toll-like receptors (TLRs), modulation of the gut microbiota, stem cell therapy, fibrosis management, interleukins (ILs) regulation, and oxidative stress mitigation. Additionally, advances in precision medicine, biologics, small molecule inhibitors, and microbiome modulation techniques were explored. Results: The investigation unveiled promising therapeutic targets and provided insights into recent breakthroughs that herald a transformative era in the therapeutic landscape for IBD. Advances in precision medicine, biologics, small molecule inhibitors, and the exploration of microbiome modulation techniques stood out as pivotal milestones in the field of gastroenterology. Conclusions: The findings offer renewed hope for enhanced efficacy, reduced side effects, and improved patient outcomes in the treatment of IBD. These innovative approaches necessitate continual exploration and underscore the urgent need for novel strategies in IBD management, potentially revolutionizing the realm of gastroenterology.
Dietary (poly)phenols mitigate inflammatory bowel disease: Therapeutic targets, mechanisms of action, and clinical observations

Paige E Jamieson,Franck Carbonero,Jan F Stevens

DOI: https://doi.org/10.1016/j.crfs.2023.100521

2023-05-18

Abstract:Inflammatory bowel diseases (IBD), which include Crohn's disease and ulcerative colitis, are a rapidly growing public health concern worldwide. These diseases are heterogeneous at the clinical, immunological, molecular, genetic, and microbial level, but characteristically involve a disrupted immune-microbiome axis. Shortcomings in conventional treatment options warrant the need for novel therapeutic strategies to mitigate these life-long and relapsing disorders of the gastrointestinal tract. Polyphenols, a diverse group of phytochemicals, have gained attention as candidate treatments due to their array of biological effects. Polyphenols exert broad anti-inflammatory and antioxidant effects through the modulation of cellular signaling pathways and transcription factors important in IBD progression. Polyphenols also bidirectionally modulate the gut microbiome, supporting commensals and inhibiting pathogens. One of the primary means by which gut microbiota interface with the host is through the production of metabolites, which are small molecules produced as intermediate or end products of metabolism. There is growing evidence to support that modulation of the gut microbiome by polyphenols restores microbially derived metabolites critical to the maintenance of intestinal homeostasis that are adversely disrupted in IBD. This review aims to define the therapeutic targets of polyphenols that may be important for mitigation of IBD symptoms, as well as to collate evidence for their clinical use from randomized clinical trials.
A Review of Dietary Therapy for IBD and a Vision for the Future

Nicole Green,Talya Miller,David Suskind,Dale Lee

DOI: https://doi.org/10.3390/nu11050947

IF: 5.9

2019-04-26

Nutrients

Abstract:Inflammatory bowel disease (IBD) is a chronic inflammatory condition affecting the gastrointestinal tract. The rising incidence of IBD has been associated with urbanization and shifts toward a Westernized diet. The intestinal microbiome has been a focus of disease pathogenesis and also therapeutic intervention. Dietary therapy for IBD has been well-studied with exclusive enteral nutrition, a formula-based diet with the exclusion of foods. In addition, interest in food-based exclusion diets has been increasing, with patients and families leading the charge. Challenges with dietary therapy for IBD include the lack of understanding of a detailed mechanistic pathway to explain the impact of diet on IBD pathogenesis and the difficult nature of designing and implementing dietary clinical trials. Epidemiological studies have demonstrated associations and intervention studies have demonstrated efficacy, but specific dietary targets remain as hypotheses at present. Current IBD therapy focuses on suppression of the immune system, yet the incomplete efficacy of present drugs suggests that other therapies must be developed and employed. Dietary interventions, with known ability to modulate the intestinal microbiome, are a unique opportunity to improve outcomes in IBD. Dietary intervention trials are challenging, and capturing both broad dietary patterns as well as exposure to individual food compounds is important. With increasing patient interest and preliminary research in dietary therapy indicating efficacy, it is imperative to further advance the science of utilizing diet in IBD, as well as to support patients by proactively addressing diet within their care plan.

nutrition & dietetics
A Comprehensive Review of Dietary Approaches in Maintaining Remission of Inflammatory Bowel Diseases in Adults

Doina Istratescu,Carmen Monica Preda,Teodora Manuc,Corina Meianu,Tudor Stroie,Mircea Diculescu

DOI: https://doi.org/10.3390/medicina60071068

2024-06-28

Abstract:Inflammatory bowel disease (IBD) poses significant challenges in its management, encompassing a spectrum of conditions from Crohn's disease to ulcerative colitis. Dietary interventions have emerged as integral components of the multidisciplinary approach to IBD management, with implications ranging from disease prevention to treatment of active manifestations and addressing complications such as malnutrition. While dietary interventions show promise in improving outcomes for some patients with IBD, there is no consensus in the existing literature regarding remission maintenance in those patients. Furthermore, many patients explore dietary modifications often guided by anecdotal evidence or personal experiences and this could lead to malnutrition and decreased quality of life. This comprehensive review synthesizes existing literature to elucidate the complex interplay between diet and IBD, offering insights into the efficacy and safety of various dietary modalities in maintaining disease remission. It also highlights the importance of patient education in navigating dietary choices and potential risks associated with food avoidance, including the heightened risk of micronutrient deficiencies. Furthermore, it emphasizes the pivotal role of a multidisciplinary care team comprising clinicians and dietitians in providing personalized dietary guidance tailored to individual patient needs and goals. By synthesizing the latest evidence and providing insights into both the potential benefits and risks of dietary interventions, this review could be used as a resource for healthcare professionals and patients alike in navigating the complex landscape of dietary management in IBD.

Review article: Prevention of inflammatory bowel disease—The path forward

Anti-cytokine Therapy and Small Molecule Agents for the Treatment of Inflammatory Bowel Disease

Review article: Novel therapies in inflammatory bowel disease – An update for clinicians

Inflammatory bowel disease in 2024 and beyond

A Review of Compounds for Prevention of Colorectal Cancer

Review article: Measuring disease severity in inflammatory bowel disease – Beyond treat to target

Review article: Optimisation of biologic (monoclonal antibody) therapeutic response in inflammatory bowel disease

Research advancements and perspectives of inflammatory bowel disease: A comprehensive review

Potential interventions and interactions of bioactive polyphenols and functional polysaccharides to alleviate inflammatory bowel disease - A review

Disease prevention trials in IBD: feasibility to future outlook

Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives

Reviewing the potential of probiotics, prebiotics and synbiotics: advancements in treatment of ulcerative colitis

Gastrointestinal microbiota-directed nutritional and therapeutic interventions for inflammatory bowel disease: opportunities and challenges

Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease—authors' reply

Inflammatory Bowel Disease and Risk of Colorectal Cancer: An Overview From Pathophysiology to Pharmacological Prevention

The Role of Diet in Inflammatory Bowel Disease Onset, Disease Management, and Surgical Optimization

Interventional inflammatory bowel disease: current and future practice

Prospective therapeutic targets and recent advancements in the treatment of inflammatory bowel disease

Dietary (poly)phenols mitigate inflammatory bowel disease: Therapeutic targets, mechanisms of action, and clinical observations

A Review of Dietary Therapy for IBD and a Vision for the Future

A Comprehensive Review of Dietary Approaches in Maintaining Remission of Inflammatory Bowel Diseases in Adults